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Abstract
Capan-1 is a well-characterised BRCA2-deficient human cell line isolated from a liver metastasis of a pancreatic
adenocarcinoma. Here we report a genome-wide assessment of structural variations and high-depth exome
characterization of single nucleotide variants and small insertion/deletions in Capan-1. To identify potential somatic and
tumour-associated variations in the absence of a matched-normal cell line, we devised a novel method based on the
analysis of HapMap samples. We demonstrate that Capan-1 has one of the most rearranged genomes sequenced to date.
Furthermore, small insertions and deletions are detected more frequently in the context of short sequence repeats than in
other genomes. We also identify a number of novel mutations that may represent genetic changes that have contributed to
tumour progression. These data provide insight into the genomic effects of loss of BRCA2 function.
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Introduction
Individuals heterozygous for loss of function mutations in the
tumour suppressor gene BRCA2 are highly predisposed to a range
of different cancers. Women that inherit a mutant BRCA2 allele
have a significantly highly elevated lifetime risk of developing
breast and ovarian cancers [1]. Additionally, male breast and
prostate cancers are strongly associated with BRCA2 gene
mutations [2]. In both sexes, BRCA2 deficiency increases the risk
of developing cancers of the pancreas, stomach, gallbladder, and
bile duct, as well as melanoma [3]. The treatment of pancreatic
cancer presents significant challenges as most patients present with
locally advanced or metastatic disease and conventional anticancer
therapies show limited effectiveness; only 5% of patients with
pancreatic cancer survive beyond five years from the initial
diagnosis [4,5].
BRCA2 plays a key role in the maintenance of genomic
integrity, particularly through regulation of DNA repair by
homologous recombination repair (HR) [6] a process that is also
controlled by another tumour suppressor protein, BRCA1 [7]. HR
is a largely error-free process that restores the original sequence at
the site of a DNA double-strand breaks (DSBs) [8]. DSBs arise
relatively frequently and can be caused by normal cellular
replication as well as exogenous stress such as exposure to ionising
radiation [9]. In the absence of HR, for example due to loss of
BRCA2 function, DSBs appear to be repaired by more error-
prone processes that ultimately lead to the accumulation of gross
chromosomal rearrangements [10]. It is thought that the
utilisation of error-prone DNA repair processes in the absence of
BRCA2 function most likely fosters tumourigenesis [10]. As part of
its role in HR, BRCA2 controls the loading and removal of the
DNA recombinase RAD51 at DSBs. The resulting RAD51-
ssDNA filament mediates the search for a homologous DNA
sequence to template the repair of the DSB [11].
Despite the great interest in BRCA2 function and its role in
tumourigenesis and DNA repair, there are few tumour cell models
of BRCA2 deficiency that can be used productively in the
laboratory. Of these Capan-1 is the most well-characterised.
Capan-1 was derived from a liver metastasis in a 40-year-old
Caucasian male with a primary pancreatic adenocarcinoma
[12,13]. These cells lack a functional BRCA2 allele and instead
carry a c.6174delT allele. The single base deletion at c.6174 causes
a frameshift, (p.S1982fs*22) resulting in loss of the C-terminal
1416 amino acids of the protein [14,15]. The resultant truncated
protein lacks two BRC motifs involved in the interaction between
BRCA2 with RAD51 and ssDNA [16], as well as C-terminal
sequences thought to be required for nuclear localization of
BRCA2 and RAD51/DNA disassembly [17,18]. This truncated
BRCA2 isoform has been shown to be both cytoplasmic and
dysfunctional in HR [19,20]. In keeping with the concept that
BRCA2 dysfunction leads to genomic instability, SKY karyotype
analysis has demonstrated that Capan-1 possesses a hypotriploid
genome, with 36 defined structural rearrangements distributed
across the entire genome [21]. The majority of these rearrange-
ments are likely very complex and appear to involve more than
three chromosome segments, although two reciprocal transloca-
tions (t(6;15) and t(7;10)) have been described (www.path.cam.ac.
uk/,pawefish).
Given the considerable use of the Capan-1 cell line as a model
not only of BRCA2 dysfunction but also of pancreatic cancer, we
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21639used next generation sequencing technology to study the genomic
sequence of this cell line.
Results
DNA sequencing strategy
To identify candidate structural rearrangements we first
generated a medium-depth whole genome sequence of Capan-1.
We isolated DNA from a Capan-1 cells, and generated a 500 bp
fragment DNA library using a PCR-free approach that improves
library complexity [22]. This DNA library was sequenced using a
paired-end strategy on an Illumina GAIIx Genome Analyser,
yielding 365,811,868 raw 76 bp mate-paired reads (27.8 Gb).
After alignment to a reference human genome (hg19/build37) and
the subsequent filtration process to remove PCR duplicates and
poor-quality reads, this data gave sufficient genome coverage
(90.09%) for the study of structural rearrangements, at a median
depth of 8.55-fold (Table 1; Table S1).
To investigate the coding sequence of Capan-1 in greater depth,
we used a targeted enrichment strategy based on Agilent
SureSelect in-solution capture. We utilized the SureSelect Human
All Exon kit, designed to capture greater than 38 Mb of human
genomic DNA corresponding to the NCBI Consensus CDS
database. Two independent capture hybridizations were per-
formed on approximately 200 bp fragments of Capan-1 genomic
DNA. The resulting exome libraries were sequenced on an
Illumina GAIIx using paired-end 2676 bp sequencing runs. This
yielded 130,310,847 raw reads (9.9 Gb). Similarly to the whole
genome analysis, sequence reads from the capture process were
aligned to a reference human genome (hg19/build37) using
Burrows-Wheeler Aligner (BWA, [23]) and then filtered to remove
PCR duplicates and poor-quality reads. The percentage of reads
on target was 65%, reaching a final coverage of 98.51% for the
baited regions with a median depth of 89-fold (Table 1; Table S2),
far exceeding the 30-fold depth required to identify genetic
variants in tumour samples [24].
For both the whole genome and exome sequencing strategies,
more than 80% of reads were aligned in conjunction with their
respective mate-pair (Table 1). In the case of the whole genome re-
sequencing, 5.63% of reads mapped to a different chromosome
compared to their mate-pair, and a further 10.31% of reads were
orphaned, i.e. where the mate-pair failed to align due to excessive
N or mismatches/indels (Table 1). This supports previous low-
resolution spectral karyotype analyses (SKY) of Capan-1 that
suggest a highly rearranged genome [21]. For the exome
sequence, slightly fewer reads were aligned independently of their
mate-pair than for whole-exome sequencing, perhaps suggesting
that rearrangements within the coding region occurred less
frequently in Capan-1 than in non-genic regions (Table 1).
Sequence depth across the genome was compared to data
generated by array comparative genomic hybridization (aCGH)
(Fig. S1, Table S1). Generally the median depth for each
chromosome identified by sequencing matched the copy number
profile generated by aCGH (Fig. S1). For example, chromosomes
such as 4 and 6, that by aCGH appeared to be present in two
copies, predominantly showed even depth across their whole
length. In addition, the single copy X chromosome returned
approximately half the number of reads of chromosomes 4 and 6.
The previously reported [21,25] homozygous deletion of 9p21
involving CDKN2A, and loss of the majority of chromosome Y,
were also confirmed by sequencing (Figure 1A; Fig. S1, Table S1).
Structural variation
To identify candidate structural rearrangements, we analysed
the whole genome sequence of Capan-1 using BreakDancer [26].
We used a stringent filtering method that only identified
rearrangements supported by at least ten reads (the median depth
across the genome was 8.55x). This approach identified 354 large
structural variations in Capan-1, which were sub-classified as
intrachromosomal deletions, insertions, inversions, or inter-
chromosomal direct or inverted translocations (Fig. 1A). No
insertions were detected in this analysis, as they all fell within the
boundaries of normal fragment size distribution (1–1000 bp).
Given that Capan-1 is a BRCA2 deficient model, we
investigated the possibility that medium depth, whole genome
sequencing could be used to distinguish BRCA1 and BRCA2
deficient tumours from non-familial forms. To date, two BRCA2
deficient tumours, two BRCA1 deficient tumours, and two
BRCA1 deficient cell lines have also been subjected to medium-
depth whole genome sequencing, as part of a wider study of
primary breast tumours and cell lines [27]. We obtained the raw
data from this study [27], and processed it through our own
pipeline, which included analysis with BreakDancer. In this way,
we were able to directly compare the frequency and type of
structural rearrangements identified in Capan-1 with both BRCA
deficient and proficient primary breast tumours and cell lines
(Fig. 1B–D). Of all the genomes studied, Capan-1 exhibited the
most structural rearrangements, both inter- and intrachromosomal
(Fig. 1B). Although the sample number under study was relatively
low (n=7 BRCA mutant tumours vs. n=15 non BRCA mutant
tumours) comparison of the Capan-1 data with data from BRCA2
mutant primary breast tumours and BRCA1 mutant primary
breast tumours and cell lines did suggest a trend for BRCA
deficient samples to exhibit larger numbers of structural
rearrangements, (median number for BRCA mutant tumours =
72 rearrangements, median number for non-BRCA mutant
tumours = 41; Fig. 1C), consistent with the roles of BRCA1
and BRCA2 in maintaining genomic stability. Although this
observation was not statistically significant (p = 0.1368, Mann
Whitney), this could be attributed to the low sample size.
Moreover, as mutations in genes other than BRCA1 and BRCA2
affect HR, it is entirely possible that some of the samples classified
as ‘‘non-BRCA’’ could also have a similar HR deficiency to
BRCA1/2 mutant tumours. The percentage of total rearrange-
ments in each class was also compared across the BRCA-mutant
and non-mutant groups (Fig. 1D). In Capan-1, as in the majority
of the other genomes, intrachromosomal deletions were the most
Table 1. Summary of sequence output.
Whole genome Exome
Number of Flow-cell lanes 14 3
Insert size 500 bp 200 bp
Read lengths 2676 bp 2676 bp
Total reads 365811868 130310847
Mate-paired reads 300129823 (82.04%) 116358031 (89.29%)
Mate mapped to different
Chr
20579769 (5.63%) 2316964 (1.78%)
Orphan reads 37706652 (10.31%) 2968254 (2.28%)
Reads on baited regions - 84694542 (65%)
Median depth 8.55 89
Coverage 2788939551 (90.09%) 37068745 (98.51%)
Reference genome length 3095677412 37629603
doi:10.1371/journal.pone.0021639.t001
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or pattern of rearrangements that was specific to BRCA-mutant
cells, based on this small set of samples.
A number of gross structural rearrangements have previously
been identified in Capan-1 using spectral karyotype (SKY) analysis
[21]. However, the resolution of SKY analysis is relatively low and
in many cases the coordinate positions of many of the putative
rearrangements identified with this form of analysis cannot be
predicted with any great confidence. Given this, we only
attempted a comparative analysis of NGS data with SKY data
where the coordinate positions of SKY predicted rearrangements
could be made within ,10 Mb. This comparative analysis
suggested that six of the previously identified rearrangements
could also be identified using whole genome sequencing, but at
higher resolution (Table 2). A further complex rearrangement
between chromosomes 6, 8, and 17 had been previously suggested
by the SKY analysis, although not in sufficient detail to elucidate
the exact regions of each chromosome involved. Our analysis also
suggested complex translocations between chromosomes 6 and 8,
and between 8 and 17 (Table 2).
Interestingly, eleven of the identified interchromosomal rear-
rangements identified in Capan-1 appeared to coincide with genic
regions at both breakpoints, potentially suggesting gene fusion
events (Table 3). None of these fusions have been previously
reported in the Cancer Genome Census [28]. A further 42
rearrangements were found within a gene or upstream regulatory
regions at one breakpoint, which could also have deleterious
effects (Table S3). One of these rearrangements had a breakpoint
in a gene, ZNF521, which was recently identified as the subject of
chromosomal translocations in acute lymphoblastic leukaemia
[29]. A further 118 genes appeared to be affected by intrachro-
mosomal rearrangements (Table S4).
Exome single nucleotide variant (SNV) and Indel
discovery
To identify SNVs and small insertion/deletion (indel) events in
the coding sequence of Capan-1, we used SAMtools [30] for the
pile-up analysis of the high-depth exome sequence and subsequent
SNV calling. Small indels (1–6 bp) were identified using a custom
pipeline (see Methods). Larger indel discovery was achieved using
Pindel [31]. In the first instance, variants were filtered to exclude
those detected at a depth of less than ten reads per copy. SNVs
and indels referenced as general population polymorphisms in
dbSNP were also disregarded, as we were largely interested in the
identification of likely cancer-specific changes.
Like the majority of tumour-derived cell lines, Capan-1 does not
have a matched normal cell line from the same patient that could
be used to help identify cancer-specific changes and remove
artefacts arising from both sample production and alignment. In
light of this, we developed a process of filtration for exome
resequencing, based on cross-comparison with data obtained from
the analogous sample preparation and analysis of four normal
genome HapMap samples (NA11881 (male); NA12761, NA12813,
and NA12892 (female)) (Table S5). Using these HapMap samples,
we were able to remove artefacts arising from both sample
production (e.g. variation in hybridization efficiency) and align-
ment (e.g. homologous regions).
Analysis of the data obtained from exome resequencing of the
HapMap samples enabled us to set thresholds for homozygosity
(variant reads . 88% or , 10% total) and heterozygosity (variant
reads 33–67% total) of variants. These thresholds were used to
filter the identified SNVs and indels in the Capan-1 genome.
Furthermore, as we were interested in identifying candidate
tumour-specific mutations, we disregarded all mutations that were
also detected in the HapMap samples, as an approximate
normalisation for likely germline variation.
Table 2. Simple interchromosomal rearrangements.
SKY karyotype Simple interchromosomal rearrangements
(Ghadimi et al. 1999) Chromosome A Chromosome B
t(1;15)(q23;q15) 1:180040326 (1q25.3) 15:49200596 (15q21.2)
t(4:15)(q26:?) 4:123601213 (4q27) 15:75679575 (15q24.3)
t(6;15)(q23;q21) 6:119442950 (6q22.31) 15:47336161 (15q21.1)
t(7;10)(q21;q24) 7:61968749 (7q11.21) 10:10951669 (10p14)
t(2;9)(?;q34) 2:116377534 (2q14.1) 9:131456807 (9q34.11)
t(5;10)(?;q24) 5:134258528 (5q31.1) 10:2348187 (10p15.3)
Complex interchromosomal rearrangements.
t(6;8;17)(p10;q10;?) 6:58779888 (6p11) 8:99469184 (8q22.2)
8:30144995 (p12) 17:7168304 (p13.1)
8:118046478 (q24.11) 17:57445353 (q23.2)
8:124144079 (q24.13) 17:55207573 (q23.1)
doi:10.1371/journal.pone.0021639.t002
Table 3. Putative chromosomal rearrangements leading to
gene fusions.
Chromosome A Chromosome B
Chr:Coordinate Gene Chr:Coordinate Gene
1:240318311 PLD5 5:167115542 ODZ2
10:127575097 FANK1 13:20370053 XPO4
11:10519362 LOC100129827 2:149639082 LYPD6B
13:110066008 CARKD 7:145694385 CNTNAP2
13:110066008 CARKD 2:149639082 LYPD6B
15:47235267 GALK2 6:119442950 FAM184A
16:76691051 WWOX 7:127929929 METTL2B
17:57374747 MED13 8:118046478 SLC30A8
17:7159674 NEURL4 8:30144995 DCTN6
18:2837027 EMILIN2 8:100508052 VPS13B
20:51993485 BCAS1 6:88216683 C6orf165
doi:10.1371/journal.pone.0021639.t003
Figure 1. Structural rearrangements in Capan-1. A. Genome-wide Circos plot of the rearrangements identified in Capan-1 by BreakDancer
analysis. An ideogram of a normal karyotype is shown in the outer ring, and copy number is represented by the blue line in the middle rings. The
relative position and class of each rearrangement is depicted within the inner circle, as described in the legend. B. Comparison of the total number of
inter- and intra-chromosomal rearrangements detected by BreakDancer analysis in a panel of BRCA2, BRCA1, and non-BRCA mutated cell lines and
primary tumours. C. Samples were classified as BRCA-mutated (mut) or BRCA wild-type (wt), and the numbers of inter-, intra-chromosomal, and total
rearrangements were compared. p values refer to Mann Whitney analysis with Gaussian approximation. D. Comparison of the percentage of each
class of rearrangement in each sample. Samples are classified as BRCA2, BRCA1, and non-BRCA mutated, as in B.
doi:10.1371/journal.pone.0021639.g001
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changes across the Capan-1 genome, as defined by the aCGH
analysis. This is particularly relevant for highly rearranged and
aneuploid genomes, such as Capan-1. Based on our experience, the
use of region-specific filters for sequencing depth facilitates more
reliable variant identification. Clearly, heterozygous variants called
in single copy regions are likely to be false (most likely due to
misalignment), and elsewhere, the number of reads bearing the
variant allele can fluctuate differently depending on the copy
number status. Hence confidence thresholds were applied to both
SNV and indel discovery, requiring a minimum of 10 reads per
genomiccopy.Inaddition,atleastthreevariant readswererequired
tocall aSNVand atleastsevenvariant readsforindels,pergenomic
copy. The resulting catalogue of SNVs and indels identified in
Capan-1 are detailed in Tables S6 and S8, respectively.
Characterization of coding SNVs
Low throughput candidate gene sequencing studies in Capan-1
have previously identified three homozygous SNVs in KRAS,
SMAD4 and MAP2K4. Using exome sequencing, we were able to
detect all three of these changes: the KRAS c.35G.T mutation
that causes the clinically relevant p.G12V amino acid substitution
[32,33], the c.1028C.G SNV in SMAD4 that results in a
premature stop codon [34] and the MAP2K4 c.661G.T mutation
in Capan-1, which leads to a cancer-associated protein truncation
[35]. The appearance of all three of these mutations in the final
filtered list of exome variants, gave confidence to our analysis
pipelines (Table S6).
Using high-depth exome sequencing, we identified a total of 608
SNVs in Capan-1 that affect 1270 different transcripts (Table 4).
Most mutations (61%) were found in non-coding regions (non-
coding genes or introns), or were synonymous variants. Twenty-
four percent of the affected transcripts were modified by non-
synonymous coding changes. In total, non-synonymous SNVs
were detected in 206 different genes, 56 of which were
homozygous (Table S6). Twelve genes gained premature stop
codons, four of which were homozygous (GRIA3, GRM1, MAP2K4,
SMAD4). Significantly, the number of probable somatic coding
mutations detected for Capan-1 in this study compared very
favourably with those shown in earlier studies examining the
tumour cell lines COLO-829 (172 non-synonymous SNV) [36]
and NCI-H209 (94 non-synonymous SNV) [24]. Both of these
earlier studies identified somatic mutations by comparison with a
matched normal blood DNA control from the same patient,
suggesting that our use of HapMap exomes is an efficient
alternative for the identification of somatic mutations in Capan-
1, and other ‘‘orphan’’ cell lines.
Three of the novel potential truncating mutations were chosen
for validation by Sanger sequencing: GRM1 (c.C1458A, p.Y486*),
SMAP2 (c.C764G, p.S255*), and GLT6D1 (c.G593A, p.W198*). All
three were shown to be true SNVs, and the zygosity detected by
the exome sequencing was also confirmed by Sanger sequencing:
homozygous for GRM1, heterozygous for SMAP2 and GLT6D1
(Fig. 2A-C). GRM1 encodes a metabotropic glutamate receptor,
aberrant expression of which has been suggested to play a role in
the development of melanoma [37]. SMAP2 is an ARF1-specific
GTPase-activating protein involved in clathrin-dependent mem-
brane trafficking [38]. The GLT6D1 gene encodes an as-yet
uncharacterised glycosyltransferase-6-domain-containing protein.
All of the novel SNVs identified here were cross-referenced with
a number of online databases (SIFT [39,40], Mutation Taster
[41,42], DAVID [43,44], CGC [28,45]) to predict their ability to
modify protein function. One of the most interesting candidates
was a homozygous c.C162A mutation in FZD10, a member of the
frizzled gene family which encode Wnt ligand-binding receptors
[46]. The homozygous c.C162A variant detected in this study leads
to a non-synonymous amino acid substitution (p.N54K) at a highly
conserved residue within the putative Wnt ligand-binding site (FZ
domain) [47,48]. FZD10 is a positive regulator of the Wnt-
bCatenin-TCF signalling pathway, has been shown to be up-
regulated in primary colorectal tumours [49], and Wnt-beta
Catenin signalling is known to be aberrant in some pancreatic
adenocarcinomas [50].
Three homozygous variants were present in the tumour
suppressor DCC (Deleted in Colorectal Carcinoma), which encodes a
netrin receptor required for cell differentiation [51], and also the
induction of apoptosis in the absence of ligand [52]. Mutations and
loss of DCC have previously been implicated in pancreatic cancer,
as well as a range of other tumour types [52,53]. One of the three
novel variants detected in Capan-1 was sited in the donor splice
site of intron 20–21, four bases downstream of the critical GT
motif. The other two variants gave rise to non-synonymous protein
mutations (p.L1042 M and p.K1411T). Although neither of these
latter non-synonymous mutations have been previously reported,
both are sited close to residues of interest: p.F1039S, mutated in
adenocarcinoma [54]; and p.Y1418, a critical residue phosphor-
ylated by Fyn, and required for DCC function [55].
Cross-referencing of the SNVs detected in Capan-1 with the
Cancer Gene Consensus (CGC) [28,45] identified twelve genes
that have previously been shown to be mutated at other residues in
cancer cell lines or primary tumours. None of the variants
identified in Capan-1 in this study have been previously described.
However, the majority of these changes were non-coding or
synonymous changes (Table S7). A heterozygous non-synonymous
mutation was observed in the genome stability checkpoint factor
Ataxia Telangiectasia Mutated (ATM). However, the variant residue
(p.R1585S) lies outside of any known functional domains and it is
therefore difficult to predict the functional consequences of this
change. A second novel heterozygous non-synonymous mutation
was identified in TPR (Translocated Promoter Region), which encodes a
protein that interacts with the nuclear pore complex. This
mutation (p.V779I) encompasses a conserved residue within a
known motif common to chromosome segregation proteins,
although the valine to isoleucine substitution identified here is
likely to be neutral.
Patterns of base substitution
We wanted to assess whether the pattern of single base
substitutions in Capan-1 reflected that of other cancer genomes.
Table 4. Predicted effects of SNVs on protein function.
Exome
Novel SNVs passing filters (genes) 608
Total no. transcripts affected by SNVs 1270
Within non-coding gene 238
Intronic 280
Synonymous coding 257
Non-synonymous coding 303
Gained premature stop codon 12
Splice-site 87
59-UTR 44
39-UTR 49
doi:10.1371/journal.pone.0021639.t004
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[36], and NCI-H209 [24] each exhibit a characteristic pattern of
base substitutions, representative of UV and tobacco carcinogen
exposure, respectively. We obtained the data from these studies, in
addition to that of the glioblastoma cell line U87 MG [56], and a
basal-like breast tumour [57], for comparison with Capan-1.
Figure 2. SNVs identified in Capan-1. A. Chromatogram depicting the stop-gain SNV in GRM1 detected for Capan-1. The protein and genomic
reference sequences are shown above the chromatogram. The SNV is highlighted in blue in the reference sequence, and the affected residue is
underlined. B. As A, for SMAP2. C. As A, for GLT6D1. D. Comparison of the single base substitution frequencies in Capan-1, basal-like breast tumour,
NCI-H209, COLO-829, and U87 MG genomes. E. Comparison of the whole genome and exome-specific base substitution frequencies observed in
Capan-1.
doi:10.1371/journal.pone.0021639.g002
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did not exhibit an obvious pattern of base substitutions or a unique
signature representative of a particular mutagen. The majority of
the coding substitutions (,45%) in Capan-1 were C.T/G.A,
although these were not as predominant as observed in COLO-
829 cells where C.T transitions at dipyrimidine sites, indicative of
UV exposure, predominate [36] (Fig. 2D). Based on the limited
number of cancer genomes that have been sequenced to date, the
pattern of base substitutions observed for Capan-1 most resembles
that of U87 MG and the basal-like breast cancer, only differing
significantly in the percentage of A.G/T.C mutations (Fig. 2D).
We also compared the pattern of base substitutions in Capan-1
in the entire genome versus the exome. We observed that the
pattern was largely the same in coding and non-coding regions,
except that C.T/G.A mutations were represented at a higher
frequency in the exome, with concurrent lower numbers of A.C/
T.G substitutions (Fig. 2E).
Characterization of coding indels
As for the SNVs, novel indels identified in the Capan-1 cell line
were filtered according to copy number. We noted that 93 genes
were affected by small indels, ranging from one to six base-pairs
(Table S8). More deletions were identified compared to insertions
(Table 5), as would be expected from the use of gapped-alignment
methods. 18 of the indels (nine insertions, nine deletions) were
homozygous variants, whereas 62 were heterozygous (27 inser-
tions, 35 deletions). Similarly to the SNVs, variation effects were
classified according to transcript (163 across the 93 genes), and the
majority of indels (72%) were detected in non-coding regions. Just
13% of indels caused frameshifts and 15% affected splice-sites.
The hallmark BRCA2 c.6174delT mutation in Capan-1 [14,15] was
one of the 15 genes scored as being affected by frameshift coding
deletions.
A subset of the high-confidence coding frameshifts was validated
by PCR and conventional Sanger sequencing, using a biological
replicate genomic DNA sample. Eight novel frameshifts (homo-
zygous: PAPLN; Heterozygous: EPHB2, LRRC7, DDIT4L, ADD3,
SF1, C17orf57, and ZNF599) present in Capan-1 but not detected
in the HapMap genomes were confirmed by Sanger sequencing, in
addition to a further 17 frameshifts and 10 three base-pair indels
common to both Capan-1 and HapMap. All of the novel
frameshifts, as well as the in-frame indels, were authenticated by
Sanger sequencing (Fig. 3A–D and data not shown). Five of the
low-rate frameshifts that failed to pass the stringent filters could
not be confirmed, supporting the validity of our analysis. Some of
the genes affected by frameshifts, such as EPHB2, have been
previously associated with tumourigenesis in other organs [58],
raising the possibility that a number of these may represent novel
driver mutations.
Sequence context of indels
It has been hypothesized that defects in homologous recombi-
nation, such as those resulting from loss of BRCA2 function, may
lead to an increase in small deletions [10,59]. These may be flanked
by repetitive sequences, if alternative processes of DNA double-
strand break repair, such as non-homologous end joining or single-
strand annealing are involved in the restoration [10,15,59]. On this
basis we examined the immediate sequence context of the small
indels detected in the Capan-1 genome, and compared these to the
two BRCA2-deficient tumours sequenced in the Stephens dataset
[27], in addition to the BRCA-proficient COLO-829 and COLO-
829BLmatched pair [36]. Indels were categorized bylength(1,2,3,
or 4+ bp), and scored for whether the flanking sequence either 59 or
39 to the indel was identical to the sequence inserted/deleted
(Fig. 3E). In the Capan-1/HapMap comparison, more than 60% of
the indels detected in Capan-1 were identical to the flanking
sequence. This is significantly more than would be expected by
chance alone (50, 12.5, 3, and 0.8% respectively for a 1, 2, 3, and 4
bp indel) and was considerably greater than observed in the in
COLO-829/COLO-829Bl comparison, where presumably HR is
active. Capan-1 exhibits a greater frequency of indels associated
with homology than COLO829 despite the much higher depth of
genomic sequence generated for COLO829. Hence the observa-
tions made for Capan-1 are unlikely to be an artefact resulting from
the differences in sequencing depth. Further, the association
between indels and flanking homology remains high for all lengths
of indels in Capan-1, which contrasts with the other cell lines
(Fig. 3E). The BRCA2-deficient tumour samples PD3689a and
PD3690a have lower frequencies of indels flanked by homology,
although it is possible that these rates are under-represented due to
the low sequence depth used in their analysis (Fig. 3E). Taken
together, this observation suggests that BRCA2-deficient tumour
cells may be predisposed to a more frequent incidence of indels in
short repetitive sequences.
Discussion
Here we have generated the first comprehensive genome
sequence analysis of a BRCA2-deficient cell line. It also represents
the first such sequence of a widely used cell line derived from a
pancreatic tumour. This dataset will therefore prove useful in
deciphering the genetic contribution to both BRCA2-deficient and
pancreatic cancers.
Many of the most frequently studied cell lines, such as Capan-1,
were derived from patient tumour samples decades ago, and as
such lack matched normal controls that can be used to determine
germline variation. This study demonstrates that massively parallel
sequencing can be utilized effectively even in the study of such cell
lines. Our novel approach to filtration of the large variant dataset,
using a combination of the publicly available databases in
combination with HapMap samples prepared, sequenced, and
analysed in an analogous manner to the query, will provide a
strategy for the future evaluation of many more cell lines. Detailed
genomic characterization of these lines will be beneficial, not only
as a comparative resource for the large-scale tumour sequencing
studies, but also to assist in deciphering many unresolved
molecular and cellular observations.
Most rearrangements detected in Capan-1 are intrachromo-
somal, as in many breast tumours [27]. As would be expected, the
Table 5. Predicted effects of indels on protein function.
Exome
Novel indels passing filters (genes) 93
Insertions 41
Deletions 52
Total no. transcripts affected by indels 163
Within non-coding gene 40
Intronic 68
Frameshift, coding gene 22
Splice-site 24
59-UTR 2
39-UTR 7
doi:10.1371/journal.pone.0021639.t005
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reflect the patterns seen in other solid tumours [24,27,60], rather
than as hotspots of rearrangement observed recently in leukaemia
[61]. Interestingly, Capan-1 exhibits a greater overall number of
rearrangements than has been previously described in other
tumour types, including breast, which often show high levels of
chromosome rearrangement [24,27,36,60]. It seems possible that
this is reflective of the genomic instability that results from the loss
of BRCA2 function in HR. However, our analysis shows that, to
date, there are too few complete sequences of HR-deficient
genomes to be able to prove this with statistical significance (Fig. 1).
Capan-1 is a particularly intriguing cell line as it is both BRCA2
deficient, like many familial breast cancers [58], yet derived from a
pancreatic adenocarcinoma. Although two BRCA2-deficient tu-
mours have previously been assessed by massively parallel DNA
sequencing, this was only at low depth, sufficient for studies of
chromosomal rearrangements, but not SNPs and indels [27].
Previous genome-wide SNP analyses of pancreatic cancers using
microarrays suggested that a small number of signalling pathways
and cellular processes are altered in most pancreatic tumours [62].
Many of these core processes are also affected by the novel
variations detected here in Capan-1, including apoptosis (DCC),
the DNA damage response (ATM), GTPase-dependent signalling
(SMAP2), and Wnt signalling (FZD10), in addition to those already
established, namely KRAS and TGFb signalling (the KRAS and
SMAD4 genes respectively). Interestingly, the recent study of
genomic variation in metastases from pancreatic cancers [63]
demonstrated that most homozygous mutations in the metastasis
were already present in [58] parental tumour, hence were most
likely to represent tumour suppressors. This is an important
finding with respect to Capan-1 and other cell lines that were
derived from a metastasis rather than the primary tumour.
The most common origin of SNPs in primates is through
deamination of methyl-cytosine causing transition of cytosine to
thymine [64]. Here we also observed that such C.T transitions
constitute the most common type of base substitution in the
Capan-1 genome. Base substitution frequencies have previously
been analyzed in 24 advanced pancreatic adenocarcinomas [62]
and 11 breast tumours [65], using large-scale PCR-based
resequencing studies of protein-coding exons. Whilst C.T
transitions also predominated in both tumour types, the pattern
of substitutions differed between pancreas and breast. In
pancreatic adenocarcinomas, the vast majority of substitutions
were either C.T (53.8%) or C.A (16.6%), with all other classes
each accounting for only 5–10% of the total [62]. In contrast, the
spectra of breast tumour mutations comprised C.T (36.5%),
C.G (28.1%), and C.A (15.1%), with far fewer substitutions at A
or T bases [65]. We observed Capan-1 to be more akin to
pancreatic adenocarcinomas in terms of the pattern of exome base
substitutions, although A.G transitions were the second most
common class of mutation (Fig. 2).
The observation that the incidence of small indels in the context
of short regions of repetitive sequence occurs more frequently in
Capan-1, and to some extent in the BRCA2 deficient tumours
PD3689a and b (Fig. 3), is intriguing. Such a signature may well
indicate the use of alternative pathways of DNA double strand
break repair, such as non-homologous end joining or single-strand
annealing [10,15,59], to compensate for the lack of HR. With the
future sequencing of further BRCA deficient genomes, it will be
possible to decipher whether this is in fact a bone fide DNA
signature representative of a cellular defect in HR, which might be
used as a biomarker to identify patient populations that might
benefit from targeted therapies such as PARP inhibitors [66].
This comprehensive sequence analysis of a BRCA2-deficient
pancreatic cancer cell line provides a valuable resource that will, in
combination with large-scale genome resequencing of patient
tumour samples, facilitate the identification of new biomarkers and
targets for therapy. The compilation of such genomic datasets will
undoubtedly underlie a greater understanding of this complex
disease, and how loss of BRCA2 contributes to tumour progression.
Methods
Genomic DNA isolation
Genomic DNA was isolated from asynchronous Capan-1 cells
(ATCC Manassas, Virginia, USA) using the Gentra PureGene kit
(Qiagen), according to the manufacturers instructions. DNA was
quantified using the Quant-It PicoGreen kit (Invitrogen).
Array CGH
aCGH was performed using a 32K BAC re-array collection
(CHORI) tiling path platform, constructed at the Breakthrough
Breast Cancer Research Centre, as previously described [67,68].
Whole genome sample preparation
Four micrograms genomic DNA was fragmented to 500 bp
using a Covaris E Series instrument (Covaris Inc.). PCR-free
libraries were then prepared using the Illumina Paired-end DNA
sample prep kit, according to [22]. Final libraries were quantified
using a Bioanalyzer DNA chip (Agilent) and subsequent qPCR.
Exome sample preparation
Four micrograms genomic DNA was fragmented to 200 bp
using a Covaris E Series instrument (Covaris Inc.). Paired-end
libraries were prepared using the Next DNA sample preparation
reagent set (New England Biolabs) with custom primers. The
library was then hybridised to the 38 Mb SureSelect Human All
Exon kit (Agilent), according to the manufacturer’s instructions.
Final libraries were quantified using a Bioanalyzer DNA chip
(Agilent) and subsequent qPCR.
Massively Parallel Sequencing
Sequencing reactions were performed on an Illumina GAIIx
genome analyser using a paired-end 2x 76 bp strategy, according
to the manufacturers guidelines.
Bioinformatic analysis
Alignment. Prior to alignment, an in-house perl script was
used to filter the raw reads in order to remove identical mate pairs
that could represent PCR duplicates, as well as those in which one
or both of the reads contained a highly repeated motif or a high
number of uncalled bases (.5N). The alignment against human
genome version 19 (ensembl 56) was performed using BWA [23].
Alignment of reads with greater than 4 mismatches compared to
Figure 3. Indels identified in Capan-1. A. Chromatogram depicting the deletion of C (highlighted in blue) in PAPLN detected for Capan-1. The
genomic reference sequence is shown above the chromatogram. The arrow indicates the position of the deletion. B. As A, for deletion of C in EPHB2.
C. As A, T.C SNV and deletion of T in DDIT4L. D. As A, deletion of AG in ZNF599. E. Comparison of the percentage of indels of 1, 2, 3, or .4 bp length
that are flanked by homology in Capan-1, COLO-829, COLO-829BL, PD3689a, and PD3690a. Homology is defined as having the same sequence as the
inserted or deleted bases either immediately 59 or 39 to the indel, as represented by the examples.
doi:10.1371/journal.pone.0021639.g003
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reads with up to 5 equal-alignment-quality hits. To facilitate
detection of small indels and SNPs, a combination of both
mismatches and up to one gap in a single read was permitted,
using default penalty parameters.
SAMTools [30] was utilized for both post-alignment filtering
and the calling of SNVs. The rmdup option was used to assure that
PCR duplicates had been completely discarded, and soft-clipped
reads were also removed. The pileup option was used to call SNVs
and obtain details of coverage and depth. Further analysis was
performed using in-house scripts (detailed below). Larger indels
were detected using Pindel [31].
Detection of SNVs and small indels. Analysis was
performed on the exome rather than whole genome data as we
were most interested in the identification of coding mutations, and
as the exome had been sequenced to a much higher depth thus
precluded structural false positives. The exomes of four genotyped
normal genome HapMap samples (NA11881 (male); NA12761,
NA12813, and NA12892 (female)) were sequenced and analysed
in an identical manner to Capan-1 in order to normalize for copy
number variation and filter for common genome polymorphisms.
All variants detected in the HapMap samples were disregarded in
Capan-1 as these were most likely to be false positive (for technical
or misalignment reasons) or non-somatic. The remaining variants
were subsequently filtered. The aCGH data was used to estimate
copy number status of each genomic region, and this was
incorporated into the filtration. Heterozygous variants in single
copy regions were discarded, and elsewhere, a minimum number
of reads bearing the variant allele per copy was required. The
identification of indels based on alignment analyses is more biased
that SNP identification, leading to different variant features.
Hence, we used different filtering premises depending on whether
the variant was a SNP or an indel, but took into consideration the
copy number status in both cases.
For SNP filtering, the concordant genotypes for all four
HapMap samples were used to establish that SNPs with a variant
rate (number of reads bearing the variant allele as a fraction of the
total number of reads in that position) greater then 0.88 or less
than 0.10 (data not shown) should be considered as homozygous
variants for variant and reference allele, respectively. We observed
that the heterozygous variant rate fluctuated from 0.33 to 0.67
(data not shown). In order to discard false variants located in low
depth regions (problematic regions), we applied a confidence
threshold of 10 reads per genomic copy.
For indel filtering, variants with a variant rate greater than 0.81
were considered to be homozygous. A threshold of 10 reads per
genomic copy was applied, and only those variants where the
number of reads bearing the variant allele was 0.75x the number
of reads estimated to correspond to one genomic copy were
considered (calculated as the depth at each position divided by the
copy number for that region, e.g. a minimum of 15 variant reads
in a 3 copy region with a depth of 60).
After filtering processes, remaining variants were classified
according to their functional consequences. We used an in-house
perl script to extract this information from Ensembl (www.
ensembl.org) using the PerAPI application, checking functional
consequences of each variant in every affected transcript for the
gene. We also distinguished between previously described and
novel variants using this tool.
Structural variations. These were identified using
BreakDancer [26] with default parameters. Filtering process was
based on depth, keeping those rearrangements supported by at
least 10 different mate pairs. For intrachromosomal
rearrangements, insert size should be greater than 1 kb,
according to the variability in the insert size produced by the
technique. Capan-1 is a highly rearranged tumour cell line
according to SKY karyotype [21], thus is not surprising that a high
number of interchromosomal rearrangements passed the filtering
process. As no normal match is available, we manually checked all
regions involved in interchromosomal rearrangements in order to
exclude those regions showing sufficient homology to represent a
strong possibility of being false positives due to misalignments.
Sanger sequencing
Sanger sequencing was used to validate our analysis pipeline
using standard protocols (see also Table S9). Primers were
confirmed to yield unique products from genomic DNA using
the UCSC In Silico PCR tool [69].
Supporting Information
Table S1 Coverage variation in Capan-1 whole genome
sequence. Median, mean, minimum and maximum values of the
depth are shown for each cytoband region. In addition, global
median value of the depth for each chromosome and for the whole
genome are shown.
(XLS)
Table S2 Coverage variation in Capan-1 exome cap-
ture. Median, mean and standard deviation values of the depth
and coverage were calculated for the rbaited region for each
chromosome and for the whole exome baited regions set.
(XLS)
Table S3 Interchromosomal rearrangements correlat-
ing with genic regions. Candidate interchromosomal rear-
rangements at genic sites are listed.
(XLS)
Table S4 Intrachromosomal rearrangements correlat-
ing with genic regions. Candidate intrachromosomal rear-
rangements at genic sites are listed.
(XLS)
Table S5 Coverage variation in HapMap exome cap-
ture. Sequence coverage from a WEC analysis in four HapMap
samples is shown.
(XLS)
Table S6 SNVs identified from exome resequencing of
Capan-1. Whole set of variants identified in CAPAN1 WEC data
after the filtering process.
(XLS)
Table S7 Novel SNVs identified in Capan-1 that corre-
late with genes listed in the Cancer Genome Census. List
of variants found in CAPAN1 located on cancer related genes,
according to the Cancer Gene Census.
(XLS)
Table S8 Indels indentified from exome resequencing
of Capan-1. List of indel variants identified in CAPAN1 WEC
data after filtering process.
(XLS)
Table S9 Number of SNVs and Indels validated by
Sanger sequencing. List of Sanger sequencing validated SNVs
and Indels are shown.
(XLS)
Figure S1 aCGH data for CAPAN1. Copy number status was
calculated based upon an aCGH analysis. Haploid regions were
estimated to present a log2 value between 21 and 20.45, diploid
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log2 value ,0.05–0.30 and tetraploid regions a log2 value of
,0.30–0.55. Regions presenting values greater than 0.55 were
considered pentaploid for filtering purposes.
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